Sagimet Biosciences Inc.

NasdaqGM SGMT

Sagimet Biosciences Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Sagimet Biosciences Inc. Revenue is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a -100.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Sagimet Biosciences Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 2.00 M.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
NasdaqGM: SGMT

Sagimet Biosciences Inc.

CEO Mr. David A. Happel
IPO Date July 17, 2023
Location United States
Headquarters 155 Bovet Road
Employees 8
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

StockViz Staff

January 15, 2025

Any question? Send us an email